^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + itacnosertib (TP-0184) (ACVR1 inhibitor, TGF-β RI antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax
Published date:
11/25/2023
Excerpt:
Treatment with TP-0184 or in combination with BCL2 inhibitor, venetoclax dramatically inhibited leukemia growth in FLT3-mutated AML cell lines and patient-derived xenograft models in a dose-dependent manner...TP-0184 is a novel potential therapeutic tool for AML with FLT3 mutations.
DOI:
10.1038/s41375-023-02086-6
